Patent Relating To Glaucoma Drug Not Obvious, Board Says
ALEXANDRIA, Va. — In a Sept. 20 final written decision, the Patent Trial and Appeal Board confirmed the patentability of 28 claims of a patented multidose, self-preserved ophthalmic composition for the...To view the full article, register now.
Already a subscriber? Click here to view full article